Understanding the Risks of Popular Weight Loss Medications
The Growing Concern Over Weight Loss Drugs
The increasing use of weight loss medications such as Ozempic, Wegovy, and Mounjaro has made treatments for obesity and diabetes more accessible globally. While many are excited about the advantages these drugs offer, recent studies indicate that they may also pose serious and unforeseen risks, including a heightened likelihood of developing various types of arthritis, osteoporosis, and gout. As individuals seek rapid weight loss and improved blood sugar levels through GLP-1 receptor agonists, healthcare professionals are advising patients to be aware of both the benefits and potential long-term consequences.
Recent findings shared at the annual meeting of the American Academy of Orthopedic Surgeons revealed that numerous patients experienced significant tendon injuries following minor accidents. This prompted researchers to investigate whether GLP-1 medications might have broader effects on bone and connective tissue health. Dr. John Horneff, an orthopedic surgery associate professor at the University of Pennsylvania and the study's lead author, stated, “While these medications have considerable benefits, they can lead to reduced food and nutrient intake.”
The ongoing study, which has yet to be published in a peer-reviewed journal, analyzed five years of medical records from over 146,000 adults diagnosed with both obesity and Type 2 diabetes, comparing those on GLP-1 drugs with those who were not. Although the records did not specify which GLP-1 medication each patient used, they included semaglutide (Ozempic and Wegovy) and liraglutide (Victoza and Saxenda).
The Link Between GLP-1 Medications and Osteoporosis Risk
How Do GLP-1 Medications Increase Osteoporosis Risk?
A significant concern is the potential for decreased bone density. Rapid weight loss has been consistently associated with lower bone mineral density, particularly among older adults. Given that GLP-1 medications promote quick weight loss, researchers are exploring whether they may inadvertently elevate the risk of osteoporosis. This condition weakens bones, making them more susceptible to fractures. Some studies indicate that extreme calorie restriction and fat loss may disrupt hormones that play a role in bone remodeling.
While there is no direct evidence linking GLP-1 medications to osteoporosis, healthcare providers stress that individuals with existing bone health issues—especially postmenopausal women and older patients—should monitor their bone density during treatment.
Weight Loss and Bone Health
Weight Loss Causes Bone Loss
The study found that approximately 4% of GLP-1 users developed osteoporosis, compared to just over 3% of non-users, indicating a 30% increased risk. Additionally, osteomalacia, a condition characterized by softening bones, was rare but occurred about twice as frequently among GLP-1 users. The incidence of gout was also slightly elevated, with 7.4% of GLP-1 users affected versus 6.6% of non-users, representing a 12% increased risk.
Dr. Horneff noted, “While the increase isn’t substantial, the data suggests a nearly doubled risk of experiencing some form of bone mineral density issue over five years.” Rapid weight loss can lead to a temporary rise in uric acid levels, which may trigger gout attacks in those predisposed to the condition. Some researchers suspect that the metabolic changes associated with GLP-1 weight loss drugs could heighten this risk, particularly in patients with a history of high uric acid levels or kidney problems. Symptoms of gout include:
- Sudden joint pain, often in the big toe
- Redness and swelling
- Warmth in the affected joint
- Severe tenderness
Experts recommend maintaining hydration, balanced nutrition, and gradual weight loss to help mitigate these risks.